Francisco David 4

What Happened
Francisco David, Chief Financial Officer of Organogenesis Holdings, received multiple equity awards on February 18, 2026 and had 14,541 shares withheld to satisfy tax withholding. The filing shows: 195,312 restricted stock units (RSUs) granted (0.00 price), 43,602 shares issued on vesting of a 2025 performance share award (0.00 price), and 111,358 derivative shares (0.00 price) related to an award that becomes exercisable over time. Separately, 14,541 shares were disposed (withheld) at $3.84 per share to cover $55,837 of tax liability.

Key Details

• Transaction date: February 18, 2026.
• Awards: 195,312 RSUs (F1), 43,602 vested performance shares (F2), and 111,358 derivative award shares/options (F3) — all reported at $0.00 acquisition price.
• Tax withholding/disposition: 14,541 shares withheld/disposed at $3.84 each for $55,837 (F—tax withholding).
• Vesting/exercise schedules noted in footnotes:
  • F1: RSUs vest in equal annual installments over 4 years beginning Feb 15, 2026.
  • F2: 43,602 shares issued upon settlement of a 2025 performance award tied to achieved milestones.
  • F3: Option (derivative) becomes exercisable in equal annual installments over 4 years beginning Feb 15, 2026.
• Shares owned after the transactions: not reported in the provided filing summary.
• No late-filing flag indicated in the information provided.

Context

• The RSUs and performance shares are award grants/settlements (not open-market purchases), so they reflect compensation and performance-based pay rather than an open-market vote of confidence.
• The 14,541-share disposition was a tax withholding event (common when equity awards vest or settle), not an open-market sale for cash proceeds beyond covering taxes.
• The derivative entry (111,358) appears tied to an option/award that will become exercisable over time; it does not represent immediate sale or cash exercise.

This summary is factual and based on the Form 4 transactions filed for Feb 18, 2026 (accession 0002064832-26-000060).